Page last updated: 2024-11-04

vorinostat and Cirrhosis

vorinostat has been researched along with Cirrhosis in 16 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ)."7.81Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. ( Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015)
"To determine whether daily oral administration of suberoylanilide hydroxamic acid (SAHA; vorinostat) for 5-weeks from the immediate post-injury period after CN injury would rectify CVOD by suppressing cavernosal fibrosis and normalizing HDAC pathway in a rat model of CN crush injury (CNCI) and to compare the results with those obtained using chronic administration of PDE5-inhibitors (a positive control)."4.02Rectification of cavernosal fibrosis and veno-occlusive dysfunction by administration of suberoylanilide hydroxamic acid in a rat model of cavernosal nerve injury: Comparison with a PDE5 inhibitor. ( Cho, MC; Kim, SW; Lee, J; Son, H, 2021)
"We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ)."3.81Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. ( Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015)
"This study was undertaken to evaluate the efficacy of co-treatment with suberoylanilide hydroxamic acid (SAHA) and mitomycin-C (MMC) on corneal fibrosis in an in-vivo model."3.80The efficacy of co-treatment with suberoylanilide hydroxamic acid and mitomycin C on corneal scarring after therapeutic keratectomy: an animal study. ( Kim, SW; Park, WC; Woo, JE; Yoo, YH, 2014)
"This study investigated the efficacy and safety of vorinostat, a deacetylase (HDAC) inhibitor, in the treatment of laser-induced corneal haze following photorefractive keratectomy (PRK) in rabbits in vivo and transforming growth factor beta 1 (TGFβ1) -induced corneal fibrosis in vitro."3.78Vorinostat: a potent agent to prevent and treat laser-induced corneal haze. ( Cowden, JW; Gibson, DJ; Liu, Y; Mohan, RR; Schultz, GS; Sharma, A; Tandon, A; Tovey, JC; Waggoner, MR, 2012)
"This study was conducted to evaluate cytotoxicity due to co-treatment with low-dose Mitomycin-C (MMC) and the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA) for glaucoma filtration surgery."3.76An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with mitomycin-C and a histone deacetylase inhibitor. ( Ahn, HB; Jeung, WJ; Kim, TH; Oh, HC; Park, WC; Rho, JH; Rho, SH; Yoo, YH, 2010)
" Suberanilohydroxamic acid (SAHA) however has been proposed to prevent corneal haze without any adverse effects."1.62Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells. ( Dadachanji, ZV; Das, D; Ghosh, A; Khamar, P; Krishna, L; Kumar, NR; Matalia, H; Mohan, RR; Murugeswari, P; Shetty, R; Subramani, M, 2021)
" Additional in vivo SAHA dosing studies with larger sample size are warranted."1.43Development of a novel in vivo corneal fibrosis model in the dog. ( Bunyak, F; Giuliano, EA; Gronkiewicz, KM; Hamm, CW; Kuroki, K; Mohan, RR; Sharma, A; Teixeira, LB, 2016)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's9 (56.25)24.3611
2020's5 (31.25)2.80

Authors

AuthorsStudies
Lee, J2
Cho, MC2
Son, H2
Kim, SW4
Yang, JS1
Liu, P1
Liu, JJ1
Chu, L1
Li, J2
Chen, C2
Yan, L1
Liu, TJ1
Chen, H1
Hao, DJ1
Shetty, R1
Kumar, NR1
Subramani, M1
Krishna, L1
Murugeswari, P1
Matalia, H1
Khamar, P1
Dadachanji, ZV1
Mohan, RR5
Ghosh, A1
Das, D1
Wang, K1
Tang, R1
Wang, S1
Wang, W1
Zhang, K1
Li, P1
Tang, YD1
Vella, S1
Conaldi, PG1
Cova, E1
Meloni, F1
Liotta, R1
Cuzzocrea, S1
Martino, L1
Bertani, A1
Luca, A1
Vitulo, P1
Woo, JE1
Park, WC3
Yoo, YH3
Patschan, D1
Schwarze, K1
Henze, E1
Patschan, S1
Müller, GA1
Sharma, A4
Sinha, NR1
Siddiqui, S1
Gronkiewicz, KM2
Giuliano, EA2
Kuroki, K1
Bunyak, F1
Teixeira, LB1
Hamm, CW1
Wang, Z1
Finger, SN1
Kwajah, S1
Jung, M1
Schwarz, H1
Swanson, N1
Lareu, FF1
Raghunath, M1
Iyer, A1
Fenning, A1
Lim, J1
Le, GT1
Reid, RC1
Halili, MA1
Fairlie, DP1
Brown, L1
Kim, TH2
Oh, HC1
Rho, JH2
Ahn, HB1
Jeung, WJ1
Rho, SH2
Tandon, A1
Tovey, JC1
Waggoner, MR1
Cowden, JW1
Gibson, DJ1
Liu, Y1
Schultz, GS1
Woo, JM1
Lee, DJ1
Park, JM1
Jeong, WJ1

Other Studies

16 other studies available for vorinostat and Cirrhosis

ArticleYear
Restoring erectile function by combined treatment with JNK inhibitor and HDAC inhibitor in a rat model of cavernous nerve injury.
    Andrology, 2022, Volume: 10, Issue:4

    Topics: Animals; Caspase 3; Disease Models, Animal; Erectile Dysfunction; Fibronectins; Fibrosis; Histone De

2022
Suberoylanilide hydroxamic acid attenuates epidural fibrosis via inhibiting myofibroblast differentiation and increasing fibroblast apoptosis.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:10

    Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Epidural Space; Female; Fibr

2020
Rectification of cavernosal fibrosis and veno-occlusive dysfunction by administration of suberoylanilide hydroxamic acid in a rat model of cavernosal nerve injury: Comparison with a PDE5 inhibitor.
    Andrology, 2021, Volume: 9, Issue:2

    Topics: Animals; Disease Models, Animal; Fibrosis; Histone Deacetylases; Impotence, Vasculogenic; Male; Nerv

2021
Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells.
    Scientific reports, 2021, 02-23, Volume: 11, Issue:1

    Topics: Adult; Apoptosis; Cells, Cultured; Collagen Type IV; Epithelium, Corneal; Female; Fibrosis; Humans;

2021
SAHA could inhibit TGF-β1/p38 pathway in MI-induced cardiac fibrosis through DUSP4 overexpression.
    Heart and vessels, 2022, Volume: 37, Issue:1

    Topics: Animals; Fibroblasts; Fibrosis; Heart Diseases; Histone Deacetylase Inhibitors; MAP Kinase Signaling

2022
Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile.
    Scientific reports, 2018, 07-24, Volume: 8, Issue:1

    Topics: Adult; Aged; Bronchiolitis Obliterans; Bronchoalveolar Lavage Fluid; Cell Differentiation; Cell Line

2018
The efficacy of co-treatment with suberoylanilide hydroxamic acid and mitomycin C on corneal scarring after therapeutic keratectomy: an animal study.
    Current eye research, 2014, Volume: 39, Issue:4

    Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cicatrix; Corneal Diseases; Cytokin

2014
Endothelial autophagy and Endothelial-to-Mesenchymal Transition (EndoMT) in eEPC treatment of ischemic AKI.
    Journal of nephrology, 2016, Volume: 29, Issue:5

    Topics: Actins; Acute Kidney Injury; Animals; Autophagy; beta-Galactosidase; Cells, Cultured; Disease Models

2016
Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.
    Molecular vision, 2015, Volume: 21

    Topics: Cell Transdifferentiation; Cells, Cultured; Cornea; Corneal Diseases; Corneal Injuries; Fibroblasts;

2015
Development of a novel in vivo corneal fibrosis model in the dog.
    Experimental eye research, 2016, Volume: 143

    Topics: Actins; Animals; Biomarkers; Burns, Chemical; Cornea; Corneal Diseases; Disease Models, Animal; Dogs

2016
Molecular mechanisms of suberoylanilide hydroxamic acid in the inhibition of TGF-β1-mediated canine corneal fibrosis.
    Veterinary ophthalmology, 2016, Volume: 19, Issue:6

    Topics: Animals; Cells, Cultured; Cornea; Dogs; Fibrosis; Histone Deacetylase Inhibitors; Hydroxamic Acids;

2016
Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?
    The European respiratory journal, 2009, Volume: 34, Issue:1

    Topics: Actins; Anti-Inflammatory Agents; Cell Line; Cell Proliferation; Collagen; Epigenesis, Genetic; Fibr

2009
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.
    British journal of pharmacology, 2010, Volume: 159, Issue:7

    Topics: Animals; Desoxycorticosterone; Fibrosis; Heart; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hy

2010
An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with mitomycin-C and a histone deacetylase inhibitor.
    Archives of pharmacal research, 2010, Volume: 33, Issue:8

    Topics: Alkylating Agents; Animals; Apoptosis; Cells, Cultured; Conjunctiva; Drug Therapy, Combination; Epit

2010
Vorinostat: a potent agent to prevent and treat laser-induced corneal haze.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2012, Volume: 28, Issue:4

    Topics: Actins; Animals; Cells, Cultured; Cornea; Corneal Keratocytes; Corneal Opacity; Dose-Response Relati

2012
Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery.
    Current eye research, 2008, Volume: 33, Issue:3

    Topics: Alkylating Agents; Animals; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Caspase 3; C

2008